EUCTR2018-002998-21-BE进行中（未招募）1 期
A phase III, multicenter, randomized, open-label trial toevaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient is = 18 years-old at the time of PICF signature
- •- Patient is female with known menopausal status at the time of randomization or initiation of adjuvant ET (whichever occurs earlier), or male.
- •- Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis (i.e. date of the pathology report that
- •confirmed the BC diagnosis) within 18 months prior to randomization.
- •- Patient has breast cancer that is positive for ER and/or PgR
- •- Patient has HER2-negative breast cancer
- •- Patient has available archival tumor tissue from the surgical specimen
- •- Patient after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and who belongs to one of the following categories (anatomic stage group II or III)
- •- If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the
- •institutional guidelines
- •- If indicated, patient has completed adjuvant radiotherapy according to the institutional guidelines
- •- Patient has no contraindication for the adjuvant ET in the trial and is planned to be treated with ET for 5 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4245
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 755
排除标准
- •- Patient has received any CDK4/6 inhibitor
- •- Patient has received prior treatment with tamoxifen, raloxifene or AIs for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. Patient is concurrently using hormone replacement therapy.
- •- Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or
- •more for doxorubicin, or 900 mg/m² or more for epirubicin.
- •- Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET
- •- Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to
- •AJCC 8th edition) and/or evidence of recurrence after curative surgery.
- •- Patient is concurrently using other anti-neoplastic therapy with the exception of adjuvant ET
- •- Patient has had major surgery, chemotherapy or radiotherapy within 14 days prior to randomization
- •- Patient has not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies
- •- Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was
- •completed within 2 years before randomization
- •- Patient has known HIV infection, Hepatitis B or C infection
- •- Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
- •- Patient:
- •- is currently receiving any of the following substances within 7 days before randomization - Concomitant medications, herbal supplements, and/or fruits that are known as strong inhibitors or inducers of CYP3A4/5 or Medications that have a narrow therapeutic window and are predominantly
- •metabolized through CYP3A4/5
- •- is currently receiving or has received systemic corticosteroids = 2 weeks prior to starting trial
- •- Patient has impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments
- •- Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the
- •Investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol
- •- Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational drug(s) (whichever is longer), or participation in any other type of medical research judged not to be scientifically or medically compatible with this trial. If the patient is enrolled or planned to be enrolled in another study that does not involve an investigational drug, the agreement of the Medical Monitor is required to establish eligibility.
- •- Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.
- •additional exclusion criteria as per full protocol may apply.
研究者
相似试验
进行中（未招募）
1 期
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib withendocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancerhormone receptor-positive, HER2-negative, early breast cancerMedDRA version: 20.0Level: LLTClassification code 10006203Term: Breast cancer stage unspecifiedSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2018-002998-21-FRovartis Pharma AG4,000
招募中
1 期
Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104CTIS2022-501969-42-00Translational Research In Oncology597
招募中
Unknown
Regorafenib-pembrolizumab vs. TACE/TARE in intermediatestage HCC beyond up-to-7 (REPLACE)Diseases of the digestive systemKCT0009093Inje University Haeundae Paik Hospital496
招募中
3 期
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer2023-510357-42-00Novartis Pharma AG2,394
进行中（未招募）
1 期
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib withendocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancerhormone receptor-positive, HER2-negative, early breast cancerMedDRA version: 20.0Level: LLTClassification code 10006203Term: Breast cancer stage unspecifiedSystem Organ Class: 100000004864MedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2018-002998-21-PLovartis Pharma AG5,000